How have HPPI shares performed in 2024?

HedgePath Pharmaceuticals' stock was trading at $0.0920 at the start of the year. Since then, HPPI stock has decreased by 25.5% and is now trading at $0.0685. View the best growth stocks for 2024 here .

What other stocks do shareholders of HedgePath Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other HedgePath Pharmaceuticals investors own include TransAtlantic Petroleum (TAT) , Eaton (ETN) , Diamond Offshore Drilling (DO) , Correvio Pharma (CORV) , Clorox (CLX) , CIT Group (CIT) , Bank of Montreal (BMO) , Blue Sphere (BLSP) , BJ's Wholesale Club (BJ) and Alimentation Couche-Tard (ATD.B) .

How do I buy shares of HedgePath Pharmaceuticals?

Shares of HPPI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:HPPI

HedgePath Pharmaceuticals (HPPI) Stock Price, News & Analysis

→ Strange new buyer driving up gold (From Stansberry Research) (Ad)

Free HPPI Stock Alerts

$0.07

0.00 (0.00%)

(As of 04/18/2024 ET)

Compare

Today's Range: $0.07
▼
$0.07
50-Day Range: $0.05
▼
$0.08
52-Week Range: $0.04
▼
$0.32

Volume: N/A
Average Volume: 19,283 shs
Market Capitalization: $25.38 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Financials SEC Filings

Get HedgePath Pharmaceuticals alerts:

Ad Behind the Markets

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

About HedgePath Pharmaceuticals

HedgePath Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for patients with cancers and non-cancerous proliferation disorders in the United States. It primarily focuses on the development of therapies for skin, lung, and prostate cancers. The company's Hedgehog signaling pathway is a primary regulator of cellular processes in vertebrates, including stem cell maintenance, cell differentiation, tissue polarity, and cell proliferation. It also develops super bioavailability (SUBA)-itraconazole oral capsules for patients with basal cell carcinoma nevus syndrome. SUBA-Itraconazole is a patented itraconazole formulation that enhances the absorption of itraconazole to enhance the bioavailability of orally administered drugs that are poorly soluble. The company was founded in 1992 and is headquartered in Tampa, Florida. HedgePath Pharmaceuticals, Inc. is a subsidiary of Mayne Pharma Ventures Pty Ltd.

HPPI Stock Price History

30 days | 90 days | 365 days | Advanced Chart

HPPI Stock News Headlines

February 17, 2024 | wsj.com

Eagle Pharmaceuticals Inc.

See More Headlines

Receive HPPI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for HedgePath Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Commercial Physical Research
Sub-Industry: N/A
Current Symbol: OTCMKTS:HPPI
CUSIP: N/A
CIK: 1042418
Web: www.hedgepathpharma.com
Phone: 813-509-2417
Fax: N/A
Employees: 2
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-4,550,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: -246.03%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.76
Quick Ratio: 6.76

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.01) per share
Price / Book: -6.85

Miscellaneous

Outstanding Shares: 370,446,000
Free Float: N/A
Market Cap: $25.38 million
Optionable: Not Optionable
Beta: -1.16

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Nicholas Jon Virca (Age 73)
Pres & CEO
Mr. Garrison J. Hasara CPA (Age 50)
CPA, CFO, Treasurer, Sec. & Chief Compliance Officer

Key Competitors

View All Competitors

HPPI Stock Analysis - Frequently Asked Questions

How have HPPI shares performed in 2024?: HedgePath Pharmaceuticals' stock was trading at $0.0920 at the start of the year. Since then, HPPI stock has decreased by 25.5% and is now trading at $0.0685.
View the best growth stocks for 2024 here.
What other stocks do shareholders of HedgePath Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other HedgePath Pharmaceuticals investors own include TransAtlantic Petroleum (TAT), Eaton (ETN), Diamond Offshore Drilling (DO), Correvio Pharma (CORV), Clorox (CLX), CIT Group (CIT), Bank of Montreal (BMO), Blue Sphere (BLSP), BJ's Wholesale Club (BJ) and Alimentation Couche-Tard (ATD.B).
How do I buy shares of HedgePath Pharmaceuticals?: Shares of HPPI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:HPPI) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial